US03589W1027
© Globe Newswire
16.01.2026
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
ANNX
LISTED
NASDAQ
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
13.11.2025
ANNX
LISTED
NASDAQ
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
News Preview
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public of...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
12.11.2025
ANNX
LISTED
NASDAQ
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
News Preview
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of sh...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.08.2025
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new n...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
ANNX
LISTED
NASDAQ
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
News Preview
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2025
ANNX
LISTED
NASDAQ
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
News Preview
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2025
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to two new...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
ANNX
LISTED
NASDAQ
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
News Preview
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2025
ANNX
LISTED
NASDAQ
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
News Preview
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.04.2025
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.04.2025
ANNX
LISTED
NASDAQ
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
News Preview
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
ANNX
LISTED
NASDAQ
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
News Preview
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ANNX
LISTED
NASDAQ
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief ex...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2024
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine ne...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven n...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
ANNX
LISTED
NASDAQ
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
News Preview
Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2024
ANNX
LISTED
NASDAQ
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
News Preview
Enhanced protection of vision with ANX007 treatment in healthier eyes...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.08.2024
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2024
ANNX
LISTED
NASDAQ
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
News Preview
Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phase 3 Trial; Potential to be First Targeted Therapy for GBS; Topline Real-World Evidence (RWE) Comparability Data Now Expected by Year-End 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
ANNX
LISTED
NASDAQ
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
News Preview
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
ANNX
LISTED
NASDAQ
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
News Preview
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2024
ANNX
LISTED
NASDAQ
Annexon Announces Pricing of $125 Million Underwritten Public Offering
News Preview
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced u...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2024
ANNX
LISTED
NASDAQ
Annexon Announces Proposed Public Offering of Common Stock
News Preview
BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has commenced an underwritten pub...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
ANNX
LISTED
NASDAQ
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
News Preview
Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2024
ANNX
LISTED
NASDAQ
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
News Preview
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
ANNX
LISTED
NASDAQ
Annexon Biosciences to Present at the Bank of America Health Care Conference
News Preview
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief exe...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
ANNX
LISTED
NASDAQ
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
News Preview
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
